Health Technology · Pharmaceuticals: Major · NSE: ERIS · data 2026-10-09
Eris Lifesciences Ltd
Health check: Strong (6.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,170.7
Market cap
₹15,943 cr
P/E
24.9
P/B
—
ROE
18.3%
ROCE
15.6%
Debt / equity
0.6
Dividend yield
0.63%
1-year return
-27.5%
52-week high
₹1,740
52-week low
₹1,141
Operating margin
26.6%
Growth
| Revenue (last 12 months) | ₹3,230 cr |
| Net profit (last 12 months) | ₹644 cr |
| Sales growth, 3 years (yearly) | 22.9% |
| Profit growth, 3 years (yearly) | 17.5% |
Similar companies
OneSource Specialty Pharma Limited (ONESOURCE) · Cohance Lifesciences Ltd (COHANCE) · Alivus Life Sciences Ltd (ALIVUS) · Alembic Pharmaceuticals Limited (APLLTD) · NATCO Pharma Limited (NATCOPHARM)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ERIS in NSE Scanner →